证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 莱绅通灵(603900.SH) 投资评级 上次评级 蔡昕妤 商贸零售分析师 执业编号：S1500523060001 联系电话：13921189535 邮 箱：caixinyu@cindasc.com [Table_Title] 莱绅通灵(603900.SH)25H1 点评：产品转型顺 产品转型顺畅，黄金镶嵌表现亮眼。25H1，黄金品类收入实现突破性增长， 黄金销售占比 80%，镶嵌黄金收入同增 200%，镶嵌钻石饰品/传统黄金饰 品/翡翠饰品/其他产品收入 4.79/3.22/0.24/0.40 亿元，同比+68%/+11%/- 14%/+46%。 线下直营、加盟渠道收入均实现较快增长，打造千万级标杆门店规划稳步 推进。分渠道，25H1 直营/加盟/线上收入分别为 5.73/0.98/1.95 亿元，直 营店单店效益稳步提升，直营收入同增 47%，加盟业务收入同比增长 109%，线上业务在去年高基数情况下仍保持稳健体量。基于现有千万级门 店年化表现，公司全年规划 50 家千万级直营店及 15 ...

Investment Rating - The report assigns a "Buy" rating for Kanglong Chemical (300759) based on its performance and growth potential [13]. Core Views - The overall performance of the company shows steady growth, with laboratory services and CMC services contributing significantly to revenue increases [2][3]. - The company maintains a full-year revenue growth guidance of 10-15% for 2025, supported by stable new order growth across its four main business segments [3]. Summary by Sections Financial Performance - In H1 2025, the company achieved revenue of 6.441 billion yuan, a year-on-year increase of 14.9%, and a net profit attributable to shareholders of 700 million yuan, a decline of 37.0% [1]. - The adjusted net profit attributable to shareholders was 756 million yuan, up 9.5% year-on-year, with operating cash flow increasing by 28.06% to 1.408 billion yuan [1]. Business Segments - **Laboratory Services**: Revenue reached 3.892 billion yuan, up 15.5% year-on-year, with a gross margin of 44.9%, an increase of 0.9 percentage points. New orders in this segment grew by over 10% [2]. - **CMC Services**: Revenue was 1.390 billion yuan, an 18.2% increase year-on-year, with a gross margin of 30.2%, up 2.4 percentage points. New orders in this segment grew by approximately 20% [2]. - **Clinical Research Services**: Revenue was 939 million yuan, an 11.4% increase year-on-year, with a gross margin of 12.3%, slightly down by 0.3 percentage points [3]. - **Large Molecule and Cell & Gene Therapy Services**: Revenue was 211 million yuan, remaining stable year-on-year, but with a gross margin of -54.7%, indicating losses due to high operational costs [3]. Customer and Regional Analysis - The company added over 480 new clients in H1 2025, contributing 128 million yuan, while existing clients generated 6.313 billion yuan, accounting for 98.01% of total revenue [4]. - Revenue from the top 20 global pharmaceutical companies was 1.168 billion yuan, a significant increase of 47.98% year-on-year [5]. - Revenue distribution by region showed North America contributing 4.073 billion yuan (up 11.02%), Europe 1.234 billion yuan (up 30.52%), and China 973 million yuan (up 15.48%) [5]. Financial Projections - Revenue projections for 2025-2027 are 13.865 billion yuan, 15.591 billion yuan, and 17.560 billion yuan, respectively, with net profits of 1.718 billion yuan, 1.985 billion yuan, and 2.302 billion yuan [7]. - The expected EPS for the same period is 0.97 yuan, 1.12 yuan, and 1.29 yuan, with corresponding P/E ratios of 31.16, 26.96, and 23.25 [7].

Investment Rating - The investment rating for Sinopec (600028.SH) is "Buy" [1] Core Views - The report indicates that Sinopec's performance in the first half of 2025 was under pressure due to weak supply and demand in the refining sector, with a significant decline in revenue and net profit compared to the previous year [1][4] - The report highlights that the company achieved a historical high in oil and gas equivalent production, despite a slight decrease in crude oil output [4][5] - The long-term investment value of Sinopec is viewed positively, given its position as a leading player in the petrochemical industry amid a competitive landscape [5][7] Financial Performance Summary - In the first half of 2025, Sinopec reported total revenue of CNY 1,409.05 billion, a year-on-year decrease of 10.60%, and a net profit attributable to shareholders of CNY 21.48 billion, down 39.83% [1] - The second quarter of 2025 saw revenue of CNY 673.70 billion, a year-on-year decline of 14.31%, and a net profit of CNY 8.22 billion, down 52.73% [2] - The average Brent oil price in the first half of 2025 was USD 71 per barrel, a decrease of 15% year-on-year, impacting the company's inventory and overall performance [4] Segment Performance Summary - The exploration and development segment achieved operating income of CNY 23.6 billion, while refining, marketing, and chemical segments reported operating incomes of CNY 3.5 billion, CNY 8 billion, and a loss of CNY 4.2 billion, respectively [4] - The company processed 120 million tons of crude oil in the first half of 2025, producing 71.4 million tons of refined oil, a decrease of 7.6% year-on-year [4] - The chemical segment showed improvement with ethylene production increasing by 16.4% year-on-year to 7.56 million tons [4] Future Earnings Forecast - The forecast for net profit attributable to shareholders for 2025, 2026, and 2027 is CNY 46.17 billion, CNY 47.86 billion, and CNY 51.73 billion, respectively, with corresponding EPS of CNY 0.38, CNY 0.39, and CNY 0.43 [7] - The report anticipates a net profit growth rate of -8.2% for 2025, followed by a recovery with growth rates of 3.7% and 8.1% in 2026 and 2027 [7]

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 沪电股份(002463) [Table_Author] 莫文宇 电子行业首席分析师 执业编号：S1500522090001 邮 箱：mowenyu@cindasc.com 相关研究 [Table_OtherReport] AI 强劲释放动能，业绩持续高速增长 沪电股份年报点评：精益求精积极布 局，AI 时代再创佳绩 AI 引擎动能强劲，投资扩产夯实中长 期成长基础 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦 B座 邮编：100031 [Table_Title] 沪电股份 2025 半年报点评：AI 服务器和交 换机延续高景气，产能瓶颈逐步突破 [Table_ReportDate] 2025 年 08 月 22 日 [Table_S 事件：沪电股份 ummary]发布 2025 年半年报，公司实现营业收入 84.94 亿元，同比 增长 56.59%；归母净利润 16.83 亿元，同比增长 47.50%；扣非归母 净利润 16 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company achieved a revenue of 1.112 billion yuan in the first half of 2025, representing a year-on-year increase of 3.87%, and a net profit attributable to shareholders of 276 million yuan, up 5.44% year-on-year [2] - The company reported a record high sales volume of 94,000 tons in Q2 2025, with stable production levels maintained since Q2 2024 [4] - The company is expanding its capacity with ongoing projects, including a 100,000-ton biomass silica project and a 30,200-ton thickener project, expected to be completed in 2025 [4] - The company maintains a gross margin of 36.67% and a net margin of 24.14% despite fluctuations in raw material prices, indicating strong competitive positioning [4] - The increasing penetration of new energy vehicles is expected to drive demand for green tire materials, with new energy vehicle sales accounting for 44.3% of total new car sales in the first half of 2025 [4] - Revenue projections for 2025-2027 are 2.426 billion yuan, 2.523 billion yuan, and 2.592 billion yuan, with net profits of 577 million yuan, 631 million yuan, and 675 million yuan respectively, reflecting growth rates of 10.4%, 4.0%, and 2.7% [4][5] Financial Summary - The company’s total revenue for 2023 was 1.81 billion yuan, with a projected growth rate of 3.7% [5] - The net profit attributable to the parent company for 2023 was 413 million yuan, with a year-on-year growth of 8.4% [5] - The projected diluted EPS for 2025 is 1.39 yuan, with a corresponding P/E ratio of 15.73x [5]

Investment Rating - The report assigns a "Buy" rating for the company Huayu Pharmaceutical-W (688553) [2] Core Insights - Huayu Pharmaceutical is a leading company in complex injectable oncology drugs, with risks from centralized procurement being gradually alleviated. By the end of 2024, the company had launched 38 products in the domestic market, with 22 in oncology and 16 in other therapeutic areas. The company achieved a revenue of 1.094 billion yuan in 2024, a year-on-year increase of 18.05%, and a net profit of 92 million yuan, up 39.55% year-on-year [5][27] - The company has shifted its focus towards international markets, with overseas revenue reaching 160 million yuan in 2024, accounting for approximately 15% of total revenue, and showing a growth of over 90% year-on-year. The company has obtained multiple GMP certifications and has launched products in 68 countries and regions [6][18] - Huayu Pharmaceutical is transitioning into a benchmark enterprise for innovative drugs, with a rich pipeline of research projects. By the end of 2024, the company had 14 Class I innovative drug projects and 5 Class II modified new drug projects, with 6 projects already in clinical stages [7][19] Summary by Sections 1. Oncology Injectable Leader, Centralized Procurement Risks Alleviated - Huayu Pharmaceutical has established itself as a leader in complex injectable oncology drugs, with a strategic transformation completed [20] - The company has actively participated in centralized procurement, with most core products selected and renewed, reducing reliance on single major products [23][27] 2. Generic Drugs: Breaking into International Markets - The company has significantly increased its product offerings, with 38 products launched by the end of 2024, reducing dependence on single products [42] - The international market has become a key growth area, with overseas revenue growing rapidly and a well-established registration system for overseas products [45][46] 3. Innovative Drugs: Transitioning Benchmark Enterprise - The company has a robust pipeline of innovative drugs, with several projects entering clinical stages, indicating a successful transition from generic to innovative drug development [19][7] - Key projects include HY-0007, a tri-target antibody fusion protein, which has the potential to become a cornerstone therapy in immuno-oncology [8][19] 4. Profit Forecast and Investment Rating - The company is expected to generate revenues of 1.054 billion yuan, 1.304 billion yuan, and 1.635 billion yuan from 2025 to 2027, with net profits projected to be -42 million yuan, 93 million yuan, and 148 million yuan respectively [9][11] - The report emphasizes the company's long-term growth potential, particularly in the context of its transition to innovative drugs and international market expansion [9][19]

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Insights - The company reported a revenue of 6.013 billion yuan for H1 2025, representing a year-on-year increase of 18.3%, while net profit decreased by 28.0% to 492 million yuan [1] - The company's proprietary brand business revenue reached 1.274 billion yuan in H1 2025, up 14.1% year-on-year, with significant growth in the European market [2] - The company is experiencing a recovery in the European vaping market, with a strong response to new compliant products, while the U.S. market is expected to stabilize due to tightening regulations [3] - The company is optimizing R&D expenses and maintaining stable operational capabilities, with a gross margin of 37.3% and an adjusted net profit margin of 12.3% in H1 2025 [4] Financial Performance Summary - For 2025-2027, the company is projected to achieve net profits of 1.228 billion yuan, 2.013 billion yuan, and 3.058 billion yuan, with corresponding P/E ratios of 103.4X, 63.1X, and 41.6X [4] - The total revenue is expected to grow from 11.799 billion yuan in 2024 to 19.291 billion yuan in 2027, with a year-on-year growth rate of 18% in 2027 [6] - The company's cash flow from operating activities is projected to improve significantly, reaching 2.680 billion yuan by 2027 [9]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company reported a revenue of 1.246 billion yuan in the first half of 2025, a year-on-year decrease of 20.9%, and a net profit attributable to shareholders of 189 million yuan, down 46.8% year-on-year [1][3] - The report highlights that the toxicology testing business is recovering, while infectious disease and chronic disease testing are under pressure. The toxicology testing revenue reached 145 million yuan, an increase of 4.3% year-on-year, with strong sales on platforms like Amazon in the U.S. [3] - The company is expected to see a recovery in revenue from respiratory disease testing as new products gain certification in both domestic and U.S. markets [3] - The report anticipates that the company's revenue will be 2.668 billion yuan in 2025, with a year-on-year growth rate of -12.9%, followed by 3.081 billion yuan in 2026 and 3.520 billion yuan in 2027, with respective growth rates of 15.5% and 14.2% [4] Financial Summary - For the first half of 2025, the company's gross profit margin was 62.87%, a decrease of 1.47 percentage points year-on-year, attributed to a higher proportion of lower-margin toxicology tests and domestic medical reform policies [3] - The company’s operating cash flow was -56 million yuan, a year-on-year decline of 128.1% [1] - The projected earnings per share (EPS) for 2025 is 0.84 yuan, with a price-to-earnings (P/E) ratio of 27.66 times based on the closing price on August 20, 2025 [4]

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The report indicates that the impact of inventory destocking in the downstream market is fading, and multiple new business initiatives are driving growth [1] - The company reported a revenue of 733 million yuan in the first half of 2025, representing a year-on-year increase of 3.73%, while the net profit attributable to the parent company was 114 million yuan, down 32.44% year-on-year [2][4] - The company is experiencing short-term pressure on its cornerstone business due to tariff disruptions, but significant progress is being made in new business areas such as blood glucose management and cardiovascular products [4] Summary by Sections Financial Performance - In the first half of 2025, the company achieved a revenue of 733 million yuan, with a year-on-year growth of 3.73%. The net profit attributable to the parent company was 114 million yuan, reflecting a year-on-year decline of 32.44% [2][4] - The second quarter of 2025 saw a revenue of 437 million yuan, which is a year-on-year increase of 2.86%, while the net profit was 62 million yuan, down 43.83% year-on-year [2] Business Segments - The cornerstone business, which includes home respiratory machine components, generated revenue of 436 million yuan, down 2.8% year-on-year, while the artificial cochlear implant components brought in 60 million yuan, down 7.5% year-on-year [4] - New business segments, particularly in home and consumer electronics components, achieved revenue of 107 million yuan, up 35.69% year-on-year, and other medical product components generated 75.72 million yuan, up 54.41% year-on-year [4] Future Outlook - The company is expected to see revenue growth from 2025 to 2027, with projected revenues of 1.862 billion yuan, 2.292 billion yuan, and 2.811 billion yuan, respectively, representing year-on-year growth rates of 16.8%, 23.1%, and 22.6% [4][5] - The net profit attributable to the parent company is forecasted to be 399 million yuan, 492 million yuan, and 603 million yuan for the years 2025, 2026, and 2027, with corresponding growth rates of 9.8%, 23.2%, and 22.4% [4][5]

Investment Rating - The investment rating for the electricity industry is "Positive" [2] Core Viewpoints - The report highlights the implementation of the "136" policy in five regions, leading to significant differentiation in the support for existing and new energy projects [7][10] - Future outlook indicates a need for clarity on pricing mechanisms, which will impact investment enthusiasm in the renewable energy sector [10] Summary by Sections Monthly Special Commentary - Five regions have introduced connection mechanisms, showing clear differentiation in support for existing and new energy projects. Shanxi has a robust protection for existing projects, while Hainan offers moderate support with lower guarantees for new projects. Liaoning provides good protection for existing projects but less favorable terms for new projects. Gansu has limited support for existing projects, and Ningxia offers the least protection overall [8][11] Monthly Sector and Key Listed Company Performance - In July, the electricity and public utilities sector fell by 0.8%, underperforming the broader market, while the Shanghai and Shenzhen 300 index rose by 3.54% [12][15] Monthly Electricity Demand Analysis - In June 2025, total electricity consumption reached 867 billion kWh, with a year-on-year growth of 5.40%. The growth rate for the secondary industry improved, while residential electricity consumption continued to rise [18][20] Monthly Electricity Supply Analysis - National electricity generation in June 2025 increased by 1.70% year-on-year, with coal power generation growing by 1.10% and solar power generation surging by 28.70% [39][40] Monthly Electricity Market Data Analysis - The average purchase price of electricity in August was 384.25 RMB/MWh, reflecting a 1.18% increase month-on-month [39] Investment Recommendations - The report suggests that the electricity sector is poised for profit improvement and value reassessment, particularly as the supply-demand balance stabilizes and new energy installations continue to grow [10][11]